Yama Mujadidi

BCA Computer Application , MSc in Information Technology and Software Engineering

Clinical Trials IT and Development Lead

Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.

Recent publications

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article

Barrett JR. et al, (2021), Nat Med, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article

Ewer KJ. et al, (2021), Nat Med, 27, 270 - 278
Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model.
Journal article

Gibani MM. et al, (2020), PLoS Negl Trop Dis, 14
Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia.
Journal article

Thindwa D. et al, (2020), Wellcome open research, 5, 66 - 66
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Internet publication

MUJADIDI YF., (2020)
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.
Internet publication

Valente Pinto M. et al, (2020), 7
Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia.
Journal article

Thindwa D. et al, (2020), Wellcome Open Res, 5
Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
Journal article

Shakya M. et al, (2019), N Engl J Med, 381, 2209 - 2218
Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials-GPPAD-02 study design and first results.
Journal article

Winkler C. et al, (2019), Pediatr Diabetes, 20, 720 - 727
Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial.
Journal article

Theiss-Nyland K. et al, (2019), Clin Infect Dis, 68, S74 - S82
Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
Journal article

Theiss-Nyland K. et al, (2019), Clin Infect Dis, 68, S67 - S73
Logistics of Implementing a Large-scale Typhoid Vaccine Trial in Kathmandu, Nepal.
Journal article

Colin-Jones R. et al, (2019), Clin Infect Dis, 68, S138 - S145
Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey.
Journal article

Voysey M. et al, (2015), Vaccine, 33, 7203 - 7210

More publications